Sign In
Buy OVID
$2.62
-0.0100 (-0.380%)
At Close: Aug 10, 2026
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 05'th Feb 2025
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, toda
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
10:31am, Tuesday, 12'th Nov 2024
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
08:00am, Wednesday, 11'th Sep 2024
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditi
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 20'th Aug 2024
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
11:00am, Monday, 19'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
11:00am, Sunday, 18'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
11:00am, Saturday, 17'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
11:00am, Friday, 16'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm
11:00am, Thursday, 15'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm
10:30pm, Wednesday, 14'th Aug 2024
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
01:15am, Wednesday, 14'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
10:10am, Tuesday, 13'th Aug 2024
Ovid Therapeutics (OVID) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.18 per share a year ago.
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
08:00am, Tuesday, 13'th Aug 2024
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditio
Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
11:55pm, Monday, 12'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm
09:15pm, Friday, 09'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
